title: Long-term disease stabilization in a patient with castration-resistant metastatic prostate cancer by the addition of lenalidomide to low-dose dexamethasone and celecoxib.
abstract: BACKGROUND
  Treatment of castration-resistant prostate cancer (CRPC) remains a challenge considering that most patients are elderly men with significant comorbidities. Alternative treatment strategies to cytotoxic therapy should be explored. There is evidence that the continuous administration of cyclooxygenase 2 (COX2) inhibitors and the immunomodulatory agents thalidomide or lenalidomide can result in longterm disease stabilization.
  
  
  METHODS
  A 70-year-old patient with castration-resistant metastatic prostate cancer was treated with a combination of low-dose dexamethasone, celecoxib and subsequently lenalidomide. The patient had longterm disease stabilization for 33 months and a very good performance status despite moderate side effects, i.e. moderate Cushing's syndrome and mild laboratory hematologic toxicity.
  
  
  CONCLUSIONS
  The addition of lenalidomide to low-dose dexamethasone and celecoxib resulted in an impressive longterm disease stabilization of CRPC in this patient, allowing him to lead an active life with a good quality of life.
authors.affiliation: Praxis für Interdisziplinäre Onkologie und Hämatologie, Breisacher Strasse 117, Freiburg i.Br., Germany. marschner@onkologie-freiburg.de
authors.forename: Norbert
authors.initials: N
authors.lastname: Marschner
authors.forename: Matthias
authors.initials: M
authors.lastname: Zaiss
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000556:secondary* / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002369:Castration; D000068579:Celecoxib; D003907:Dexamethasone / Q000008:administration & dosage; D006801:Humans; D000077269:Lenalidomide; D008137:Longitudinal Studies; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D011720:Pyrazoles / Q000008:administration & dosage; D013449:Sulfonamides / Q000008:administration & dosage; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D011720:Pyrazoles; D013449:Sulfonamides; D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide; D000068579:Celecoxib